Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: FDA Fast Track Designation
Aquestive’s Sublingual Epinephrine Film Receives FDA Fast Track Designation for Treatment...
News Wire ~ 3rd Party Press Release
-
2020/08/11
First planned PK clinical trial expected to begin during the third quarter of 2020.
Bryn Pharma Completes Dosing in Pivotal Clinical Trial Designed to Support...
News Wire ~ 3rd Party Press Release
-
2019/10/10
Nasal Spray Product is Disruptive Innovation for People at Risk of Anaphylaxis.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/10/04
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/08/08
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray
News Wire ~ 3rd Party Press Release
-
2019/02/19
Company provides a novel means of administering emergency epinephrine.
FDA Grants Fast Track Designation for Epinephrine Nasal Spray as Investigational...
News Wire ~ 3rd Party Press Release
-
2018/08/30
"A significant milestone for INSYS and our clinical development of this novel drug-device combination.”